Real-World Experience With Pasireotide Lar in Acromegaly Resistant to First-Generation Somatostatin Analogs: A Single Center 1-Year Observation

Introduction: First generation somatostatin analogs (SSAs) are the treatment of choice in persistent acromegaly after transsphenoidal surgery. However, they are effective in 25% to 45 % of patients and a second generation SSA - pasireotide LAR may be a more effective alternative. Aim Our aim was to...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Endocr Soc
Hlavní autoři: Stelmachowska-Banas, Maria, Czajka-Oraniec, Izabella Katarzyna, Tomasik, Agnieszka, Zgliczynski, Wojciech
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2021
Témata:
Neuroendocrinology and Pituitary
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8090632/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.1071
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky